- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07676032
Body Composition and Setup Errors in Radiotherapy (BODY-SET)
23. Juni 2026 aktualisiert von: Chaoxing Liu, Shijiazhuang People's Hospital
The Impact of Body Composition on Setup Errors in Patients Undergoing Radiotherapy With Thermoplastic Mask Immobilization: A Single-Center Prospective Cohort Study
This single-center prospective cohort study investigates the association between body composition parameters and setup errors in 120-150 patients receiving radiotherapy with thermoplastic mask immobilization.
Body composition (skeletal muscle mass, body fat percentage, phase angle, fat-free mass) will be measured using bioelectrical impedance analysis at baseline and at fraction 20.
Setup errors (six degrees of freedom) will be recorded via daily cone-beam computed tomography.
The primary outcome is the association between baseline body composition and setup errors.
Secondary outcomes include the relationship between body composition changes during radiotherapy and setup error evolution, and identification of threshold values for clinically significant setup error increases.
This study will provide evidence on whether body composition-beyond BMI-predicts radiotherapy setup accuracy, potentially enabling personalized immobilization and image-guided strategies.
Studienübersicht
Status
Noch keine Rekrutierung
Bedingungen
Detaillierte Beschreibung
Radiotherapy is a cornerstone of cancer treatment, with approximately 50-70% of patients requiring radiotherapy during their disease course.
Accurate patient positioning is essential for ensuring adequate target volume coverage while sparing organs at risk.
Thermoplastic masks are among the most commonly used immobilization devices; however, setup reproducibility varies considerably among patients.
Previous studies have demonstrated that patients with BMI ≥24 kg/m² exhibit significantly greater setup errors across multiple directions in breast, cervical, and thoracic cancers compared with normal-weight patients.
However, BMI is a crude anthropometric measure that cannot distinguish between fat and muscle mass-two tissue types with fundamentally different mechanical properties that may affect mask fit and positional reproducibility.
Bioelectrical impedance analysis (BIA) provides a non-invasive, convenient method for measuring body composition parameters, including skeletal muscle mass (SMM), body fat percentage (BFP), phase angle (PhA), and fat-free mass (FFM).
Phase angle, in particular, reflects cell membrane integrity and cellular mass, and has been validated as a sensitive marker of muscle quality and nutritional status in cancer patients.
However, the value of BIA-derived body composition parameters in predicting radiotherapy setup errors has not been systematically explored.
This study is a single-center, prospective observational cohort study conducted at the Department of Radiation Oncology, Shijiazhuang People's Hospital, China.
A total of 120-150 patients with pathologically confirmed malignancies receiving radical or adjuvant intensity-modulated radiotherapy (≥25 fractions) with thermoplastic mask immobilization will be enrolled.
Body composition parameters will be measured using BIA at baseline (T0) and at fraction 20 (T1).
Setup errors (six degrees of freedom: Tx, Ty, Tz, Rx, Ry, Rz) will be recorded via cone-beam computed tomography (week 1: 3 times; thereafter: weekly).
The primary outcome is the association between baseline body composition parameters and setup errors.
Secondary outcomes include the relationship between body composition changes and setup error evolution, and identification of threshold values for clinically significant setup error increases.
Data will be analyzed using multiple linear regression and generalized estimating equations.
Results will be disseminated through peer-reviewed publications and conference presentations.
Studientyp
Beobachtungs
Einschreibung (Geschätzt)
150
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Chaoxing Liu, Dr
- Telefonnummer: 86 17603119780
- E-Mail: 15130068099@163.com
Studieren Sie die Kontaktsicherung
- Name: Xiaoyan Wang, Dr
- Telefonnummer: 86 15031163260
- E-Mail: 15031163260@163.com
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Probenahmeverfahren
Wahrscheinlichkeitsstichprobe
Studienpopulation
Patients with pathologically confirmed malignancies receiving radical or adjuvant intensity-modulated radiotherapy at Shijiazhuang People's Hospital.
Beschreibung
Inclusion Criteria:
- Pathologically confirmed malignancy
- Age ≥18 years
- Receiving radical or adjuvant intensity-modulated radiotherapy (IMRT) with planned ≥25 fractions
- Immobilized with thermoplastic mask
- ECOG Performance Status 0-2
- Willing and able to provide written informed consent
Exclusion Criteria:
- Metal implants (pacemaker, artificial joints) affecting bioelectrical impedance analysis (BIA) measurements
- Severe edema or ascites
- Inability to cooperate with immobilization or CBCT scanning
- Radiotherapy interruption >5 fractions
- Pregnancy or lactation
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
High Muscle Mass Group
Patients with skeletal muscle mass above the sex-specific median
|
|
Low Muscle Mass Group
Patients with skeletal muscle mass below the sex-specific median
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
setup errors
Zeitfenster: Through study completion, an average of 6 months.
|
Six-degree-of-freedom setup errors (Tx, Ty, Tz, Rx, Ry, Rz) measured by cone-beam computed tomography (CBCT).
|
Through study completion, an average of 6 months.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Skeletal Muscle Mass
Zeitfenster: Baseline and fraction 20 (approximately 4 weeks after baseline)
|
Change in skeletal muscle mass (SMM) from baseline (T0) to radiotherapy fraction 20 (T1), measured by multi-frequency bioelectrical impedance analysis (BIA).
SMM is expressed in kilograms (kg).
|
Baseline and fraction 20 (approximately 4 weeks after baseline)
|
|
Change in Body Fat Percentage
Zeitfenster: Baseline and fraction 20 (approximately 4 weeks after baseline).
|
Change in body fat percentage (BFP) from baseline (T0) to radiotherapy fraction 20 (T1), measured by multi-frequency bioelectrical impedance analysis (BIA).
BFP is expressed as a percentage (%).
|
Baseline and fraction 20 (approximately 4 weeks after baseline).
|
|
Change in Phase Angle
Zeitfenster: Baseline and fraction 20 (approximately 4 weeks after baseline)
|
Change in phase angle (PhA) from baseline (T0) to radiotherapy fraction 20 (T1), measured by multi-frequency bioelectrical impedance analysis (BIA).
PhA is expressed in degrees (°).
|
Baseline and fraction 20 (approximately 4 weeks after baseline)
|
|
Change in Fat-Free Mass
Zeitfenster: Baseline and fraction 20 (approximately 4 weeks after baseline)
|
Change in fat-free mass (FFM) from baseline (T0) to radiotherapy fraction 20 (T1), measured by multi-frequency bioelectrical impedance analysis (BIA).
FFM is expressed in kilograms (kg).
|
Baseline and fraction 20 (approximately 4 weeks after baseline)
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Hauptermittler: Chaoxing Liu, Dr, Shijiazhuang People's Hospital
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Allgemeine Veröffentlichungen
- Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013 Jan 8;346:e7586. doi: 10.1136/bmj.e7586.
- Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.
- Kecojevic A, Ranken R, Ecker DJ, Massire C, Sampath R, Blyn LB, Hsieh YH, Rothman RE, Gaydos CA. Rapid PCR/ESI-MS-based molecular genotyping of Staphylococcus aureus from nasal swabs of emergency department patients. BMC Infect Dis. 2014 Jan 9;14:16. doi: 10.1186/1471-2334-14-16.
- Polack S, Adams M, O'banion D, Baltussen M, Asante S, Kerac M, Gladstone M, Zuurmond M. Children with cerebral palsy in Ghana: malnutrition, feeding challenges, and caregiver quality of life. Dev Med Child Neurol. 2018 Sep;60(9):914-921. doi: 10.1111/dmcn.13797. Epub 2018 May 7.
- Dai X, Feng J, Chen Y, Huang S, Shi X, Liu X, Sun Y. Traditional Chinese Medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Chin Med. 2021 Aug 3;16(1):68. doi: 10.1186/s13020-021-00469-4.
- Dou S, Ding H, Jiang W, Li R, Qian Y, Wu S, Ling Y, Zhu G. Effect of oral supplements on the nutritional status of nasopharyngeal carcinoma patients undergoing concurrent chemotherapy: A randomized controlled Phase II trial. J Cancer Res Ther. 2020;16(7):1678-1685. doi: 10.4103/jcrt.JCRT_273_20.
- Kohli K, Corns R, Vinnakota K, Steiner P, Elith C, Schellenberg D, Kwan W, Karvat A. A bioimpedance analysis of head-and-neck cancer patients undergoing radiotherapy. Curr Oncol. 2018 Jun;25(3):e193-e199. doi: 10.3747/co.25.3920. Epub 2018 Jun 28.
- Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, Valks A, Block GA, Boudville N, Cameron JD, Campbell KL, Chen SSM, Faull RJ, Holt SG, Jackson D, Jardine MJ, Johnson DW, Kerr PG, Lau KK, Hooi LS, Narayan O, Perkovic V, Polkinghorne KR, Pollock CA, Reidlinger D, Robison L, Smith ER, Walker RJ, Wang AYM, Hawley CM; IMPROVE-CKD Trial Investigators. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). J Am Soc Nephrol. 2020 Nov;31(11):2653-2666. doi: 10.1681/ASN.2020040411. Epub 2020 Sep 11.
- Bas D, Atahan C, Tezcanli E. An analysis of phase angle and standard phase angle cut-off values and their association with survival in head and neck cancer patients undergoing radiotherapy. Clin Nutr. 2023 Aug;42(8):1445-1453. doi: 10.1016/j.clnu.2023.06.020. Epub 2023 Jul 6.
- Prior-Sanchez I, Herrera-Martinez AD, Zarco-Martin MT, Fernandez-Jimenez R, Gonzalo-Marin M, Munoz-Garach A, Vilchez-Lopez FJ, Cayon-Blanco M, Villarrubia-Pozo A, Munoz-Jimenez C, Zarco-Rodriguez FP, Rabat-Restrepo JM, Luengo-Perez LM, Boughanem H, Martinez-Ramirez MJ, Garcia-Almeida JM. Prognostic value of bioelectrical impedance analysis in head and neck cancer patients undergoing radiotherapy: a VALOR(R) study. Front Nutr. 2024 Feb 22;11:1335052. doi: 10.3389/fnut.2024.1335052. eCollection 2024.
- Chen J, Guo Y, Wang C, Lin S, Shao L, Lan L, Guo F. Univariate and multivariate analysis of the styrofoam fixation device on patient setup errors in radiotherapy. J Appl Clin Med Phys. 2025 Jul;26(7):e70181. doi: 10.1002/acm2.70181.
- Ruan J, Huang X, Wang T, Mai X, Lin C, Li F, Li Y, Chi F, Li B. Impact of belly board immobilization devices and body mass factor on setup displacement using daily cone-beam CT in rectal cancer radiotherapy. J Appl Clin Med Phys. 2025 Mar;26(3):e14573. doi: 10.1002/acm2.14573. Epub 2024 Nov 29.
- Baba AY, Ahmad A, Baba OY, Shahid M. Assessing Axis-specific Set-up Errors in Rectal Cancer Radiotherapy: A Prospective Cone-beam Computed Tomography-Based Study with Body Mass Index Correlation. J Med Phys. 2025 Oct-Dec;50(4):731-736. doi: 10.4103/jmp.jmp_123_25. Epub 2025 Dec 31.
- Mulla Z, Hashem R, AlMohamad A, Weber A, Habibullah H, Abdulmoula G, Mohiuddin MG, Ujaimi R. Effect of Body Mass Factors on Setup Displacement in Gynecologic Tumors and Subsequent Effect on PTV Margins. Adv Radiat Oncol. 2022 Oct 25;8(1):101108. doi: 10.1016/j.adro.2022.101108. eCollection 2023 Jan-Feb.
- Costin IC, Marcu LG. Impact of immobilization system angle, body mass index and breast size on breast radiotherapy accuracy using EPID-only setup. Heliyon. 2025 Jan 22;11(3):e42176. doi: 10.1016/j.heliyon.2025.e42176. eCollection 2025 Feb 15.
- Wan B, Huan FK, Ge YD, Zhao RA, Zheng YT, Liang M, Zhang YX, Zhang W, Hou L, Zhang Y, Wang HK. Influence of Site, Surgery, and BMI Binary Classification on Positioning Errors in Radiotherapy for Breast Cancer Patients: A Retrospective Study. Cancer Rep (Hoboken). 2025 Sep;8(9):e70343. doi: 10.1002/cnr2.70343.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
1. Juli 2026
Primärer Abschluss (Geschätzt)
31. Dezember 2026
Studienabschluss (Geschätzt)
31. März 2027
Studienanmeldedaten
Zuerst eingereicht
18. Juni 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
23. Juni 2026
Zuerst gepostet (Tatsächlich)
30. Juni 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
30. Juni 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
23. Juni 2026
Zuletzt verifiziert
1. Juni 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- SJZPH-RO-2026-001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .